Dowden Nathan J's Form 4 filing
Entrada Therapeutics, Inc. (TRDA) · filed Mar 11, 2026
- Accession no.
- 0001873392-26-000002
- Filed
- Mar 11, 2026
- Trade date
- Mar 9-10, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $195.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dowden Nathan JCIK 0001873392 | Officer (President & COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | Common Stock | SSaleDisposed | −3,116 | $13.02 | −$40,570.32 | 210,482 | Direct | |
| Mar 10, 2026 | Common Stock | SSaleDisposed | −11,894 | $13.05 | −$155,216.7 | 198,588 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.